Alector (ALEC) vs Lineage Cell Therapeutics (LCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alector (ALEC) has outperformed Lineage Cell Therapeutics (LCTX) over the past year, losing 34.4% versus a loss of 40.5%. Over five years, LCTX leads with a -56.2% price change compared with -91.8% for ALEC. Lineage Cell Therapeutics is the larger company by market cap ($260.5 million vs $225.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | LCTX |
|---|---|---|
| Share price | $2.02 | $1.03 |
| Market cap | $225.55M | $260.49M |
| 1-day change | +5.21% | +8.70% |
| YTD return | +29.49% | -38.32% |
| 1-year return | -34.42% | -40.46% |
| 5-year return | -91.76% | -56.17% |
| EPS (TTM) | $-1.09 | $-0.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $2.09 |
| 52-week low | $1.09 | $0.88 |
| Distance from 52-week high | -40.59% | -50.72% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +63.37% | +433.98% |
| Average volume | 2.77M | 1.15M |
| Shares outstanding | 111.66M | 252.91M |
| Employees | 103 | 72 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Alector in Healthcare and Lineage Cell Therapeutics in Health Care.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Healthcare · Biotechnology · 103 employees
About Lineage Cell Therapeutics
LCTX stock →Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 72 employees
ALEC vs LCTX FAQ
Which is bigger, Alector or Lineage Cell Therapeutics?
Lineage Cell Therapeutics (LCTX) is larger, with a market capitalization of $260.49M compared with $225.55M for Alector (ALEC).
Which stock has performed better over the past year, ALEC or LCTX?
ALEC returned -34.42% over the past 12 months, compared with -40.46% for LCTX (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Lineage Cell Therapeutics in the same industry?
No. Alector is in the Healthcare sector, while Lineage Cell Therapeutics is in Health Care.